A statistical analysis (MAIC) of the ARCHES and ARANOTE studies suggests enzalutamide is more effective at delaying disease progression.

With no head-to-head trials for ARPIs, physicians use methods like MAIC to indirectly compare efficacy and safety, guiding treatment decisions.

Enzalutamide and other ARPIs are key in treating metastatic prostate cancer by blocking androgen receptors, improving patient survival rates.

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling ...

New data reveals sugemalimab significantly enhances survival rates in metastatic non–small cell lung cancer, establishing it as a key first-line treatment option.

An expert discusses the advances in managing CAR T-cell therapy toxicities, emphasizing aggressive early treatment of acute complications, the importance of coordinated long-term monitoring with ...

An expert discusses the emerging role of bispecific antibodies in lymphoma treatment, highlighting their expanding use across treatment lines—including as alternatives or bridges to CAR T-cell therapy ...

An expert discusses the evolving landscape of large B-cell lymphoma (LBCL) treatment, highlighting emerging CAR T-cell targets and bispecific antibody strategies, the potential shift toward more ...

The NCCN added critical guidance on Lambert-Eaton myasthenic syndrome to its recommendation for the diagnosis and treatment ...

Medical practices face staffing shortages and rising costs, prompting innovative strategies for health benefits to enhance ...

Discover the latest breakthroughs in oncology, including FDA approvals and innovative therapies reshaping cancer treatment ...

Precision medicine revolutionizes cancer care, empowering patients with personalized insights and targeted therapies while ...